Futura Medical plc (FAMDF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 10:49AM EST
Loading interactive chart…
- Simply Wall St.
Will Futura Medical (LON:FUM) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Simply Wall St.
Futura Medical plc (LON:FUM) is favoured by institutional owners who hold 63% of the company
A look at the shareholders of Futura Medical plc ( LON:FUM ) can tell us which group is most powerful. We can see that...
- Business Wire
Highly positive FM71 Phase 3 study results with all primary and secondary endpoints achieved, MED3000 remains on track to submit for FDA marketing authorization
GUILDFORD, England, August 31, 2022--Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces positive results from the confirmatory Phase 3 clinical study, "FM71" for MED3000, an investigational therapy for the treatment of erectile dysfunction ("ED").
© 2023 Yahoo. All rights reserved.
